Biologic Drugs For Cancer at CIOC 2027

Biologic drugs have transformed cancer treatment by harnessing the body's immune system and targeting specific cellular mechanisms in cancer. Derived from living organisms, these innovative therapies include monoclonal antibodies, immune checkpoint inhibitors, and CAR T-cell treatments. Monoclonal antibodies, such as trastuzumab and rituximab, target cancer cell antigens to enhance immune responses or deliver toxic agents directly to cancer cells. Immune checkpoint inhibitors, like pembrolizumab, work by removing inhibitory signals on immune cells, allowing them to more effectively combat cancer. CAR T-cell therapies involve modifying a patient's T-cells to recognize and destroy cancer cells more efficiently. These biologic treatments provide highly personalized and precise options, often with reduced side effects, marking a significant advancement in cancer therapy.